Morning versus evening dosing of desloratadine in seasonal allergic rhinitis: a randomised controlled study

Completed

• Conditions: Seasonal allergic rhinitis; Respiratory; Allergic rhinitis

• Registration Number: ISRCTN23032971
• Lead Sponsor: Schering-Plough AS (Norway)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-02-01
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 663

Inclusion Criteria

1. Patients 18 years or above with a minimum of two years history of SAR confirmed by either a positive skin prick test or a positive serologic allergen test to the relevant seasonal allergen
2. Clinically symptomatic with SAR at baseline/inclusion with a minimum total nasal symptom score (rhinorrhoea, congestion, itching and sneezing) of at least 6 and rhinorrhoea being minimum 2 (moderate)
3. Willingness to adhere to dosing and visit schedule
4. Females of childbearing potential have to use medically accepted methods of birth control
5. Written informed consent

Exclusion Criteria

1. Pulmonary disease, perennial rhinitis, sinusitis, rhinitis medicamentosa, pollen desensitisation during the last 6 months
2. Respiratory tract infection within the last two weeks
3. Structural nasal abnormalities (including polyps)
4. Use of oral, nasal, ocular decongestants, corticosteroids in any form (except mild dermatological group I corticosteroids allowed in only small areas), other antihistamines (oral or topical), any investigational drug during the last 30 days
5. Pregnant or nursing females

Study & Design

• Study Type: Interventional
• Study Design: Not specified